Infectious Disease

Two-dose COVID-19 vaccines significantly increase protection against hospitalization and death in people who had the illness before they were immunized.

Researchers have created a test that can predict which dengue patients will likely have mild symptoms and which should be clinically monitored for a high risk of severe illness.

Stanford Medicine scientists explain what we know, and what we don’t know, about living with COVID-19 two years after the World Health Organization declared a pandemic.

Tuberculosis lesions in the lungs have high levels of proteins that suppress the immune system. Cancer drugs that target these proteins could be used to fight the bacterial infection.

A new study has identified a way that the immune system shoots down its own cells when their anti-viral activity threatens to become friendly fire. The finding could pave the way to new treatments for autoimmune diseases.

Stanford Medicine’s clinical virology laboratory has processed its 1 millionth COVID-19 test nearly two years after becoming one of the first academic center testing sites in the country.

COVID-19 vaccines are better than infection at making antibodies to recognize new viral variants, according to a Stanford study.

Rituximab, a drug widely used in patients with lymphoma, blunts or eliminates the antibody response to COVID-19 vaccines if it is administered before them, Stanford researchers say.

A new study found that part of the Epstein-Barr virus mimics a protein made in the brain and spinal cord, leading the immune system to mistakenly attack the body’s nerve cells.

A look at antibodies in patients soon after they were infected with the virus that causes COVID-19 showed key differences between those whose cases remained mild and those who later developed severe symptoms.

Stanford infectious disease expert Jason Andrews has spent years studying the spread of tuberculosis in crowded Brazilian prisons and surrounding communities — an overlooked global health crisis.